Parkinson’s & Neurological

Important Caveat: Emerging Research, Not Established Treatment

Ibogaine for Parkinson’s disease and other neurodegenerative conditions is at an early stage of investigation. The evidence base here is fundamentally different from ibogaine for addiction or PTSD, where clinical studies and decades of observational data exist. For Parkinson’s and related conditions, we are in the territory of case reports, mechanistic hypotheses, and early compassionate-use observations.

We present this information because many patients and families facing neurodegenerative diagnoses are researching every available option — and ibogaine’s documented effects on brain chemistry suggest it deserves serious scientific attention for these conditions. But we want to be honest: this is not yet proven treatment, and anyone considering ibogaine for Parkinson’s should understand they are in experimental territory.

The GDNF Connection: Why Ibogaine May Be Relevant to Parkinson’s

Parkinson’s disease involves the progressive loss of dopamine-producing neurons in a brain region called the substantia nigra. Current treatments — primarily levodopa and dopamine agonists — manage symptoms by supplementing dopamine but do nothing to slow the underlying neurodegeneration.

Research has long suggested that GDNF (Glial Cell Line-Derived Neurotrophic Factor) has remarkable protective and restorative effects on dopaminergic neurons. In animal models, GDNF administration has reversed Parkinson’s-like symptoms and regenerated dopaminergic cells. Human trials with direct GDNF infusion into the brain have shown promising results, though delivery has been a major challenge.

Ibogaine significantly increases GDNF levels in the brain — this is one of the primary mechanisms by which it promotes recovery from addiction. The hypothesis that ibogaine’s GDNF-boosting effects might provide some benefit in Parkinson’s is scientifically plausible, though unproven in controlled human trials.

Case Reports and Patient Observations

A small number of Parkinson’s patients have sought ibogaine treatment — primarily at Mexican clinics that treat addiction and PTSD — and some have reported meaningful temporary improvements in motor function, tremor, and quality of life following treatment.

These reports are anecdotal and must be treated with appropriate skepticism. Parkinson’s symptoms naturally fluctuate; placebo effects are real; and the populations reporting improvements are self-selected. That said, the consistency of some of these reports, combined with the GDNF mechanism, has attracted the attention of researchers who believe controlled studies are warranted.

“My husband has had Parkinson’s for six years. We went to Mexico with low expectations. For three months after treatment, his tremor was noticeably reduced — not gone, but better than it had been in years. We’re going back.” — Spouse of Parkinson’s patient, Florida

Traumatic Brain Injury: Stronger Evidence

For traumatic brain injury (TBI), the evidence is considerably stronger. The Stanford study demonstrated significant cognitive improvements in veterans with TBI following ibogaine treatment — improvements in memory, processing speed, and executive function that current medicine has no other approach to achieve.

The mechanism for TBI appears to involve ibogaine’s broad neuroplasticity effects — GDNF and BDNF upregulation promoting repair and reorganization of neural circuits damaged by blast or impact injury. This is more than a hypothesis at this point: it’s what the Stanford data shows.

ALS and Other Neurodegenerative Conditions

ALS (amyotrophic lateral sclerosis) involves the progressive death of motor neurons — a different mechanism than Parkinson’s but one in which neurotrophic factors like GDNF and BDNF are also implicated. Some ALS patients have sought ibogaine treatment, but published data is essentially nonexistent.

For other neurodegenerative conditions including multiple sclerosis, progressive supranuclear palsy, and Lewy body dementia, ibogaine is even more speculative. We include these only because patients ask about them — not because we have evidence to support their use.

What Our Partner Clinics Offer for Neurological Cases

A small number of our partner clinics have experience treating patients with Parkinson’s and TBI — as opposed to addiction or PTSD. These clinics approach neurological cases with additional medical caution, adjusted protocols, and realistic expectations. They are not offering a cure; they are offering a carefully monitored opportunity to see whether ibogaine’s documented neurotrophic effects produce meaningful benefit for the individual patient.

If you’re considering ibogaine for a neurological condition, we will match you only with clinics that have experience in this area and that will be honest with you about what is and isn’t known.